LC Determination of Lercanidipine and Its Impurities Using Drylab Software and Experimental Design Procedures
Tóm tắt
The main objective in all optimization procedures is to define the most appropriate conditions for rapid, sensitive, precise, and reproducible analysis, as economically as possible. Experimental design and DryLab optimization software have been used to optimize a liquid chromatographic method for separation of lercanidipine and its three impurities. In both methods of optimization the acetonitrile content and pH of the mobile phase were factors extracted for analysis; resolution of a critical pair was output in both cases. Data obtained from both optimization methods were compared and appropriate conclusions were extracted with the objective of gaining a complete view of chromatographic behavior. Detailed description was obtained by use of a three-dimensional graph and DryLab maps. Both methods of optimization reported the most appropriate mobile phase to be a 35:65 mixture of acetonitrile and an aqueous solution of 1.5% TEA, pH adjusted to 3.0 by addition of orthophosphoric acid, at a flow rate 1.0 mL min−1. Separations were performed on a 20 × 4.6 mm, 3.5-μm particle size, C18 column, at 20 °C, with UV detection at 240 nm. The method was validated. All the results proved the reliability of the method, so it can be used for separation, identification, and simultaneous determination of these substances in the drug and in pharmaceutical dosage forms.
Tài liệu tham khảo
Baczek T, Kaliszan R, Claessens HA, van Straten MA (2001) LC–GC Europe, 2–6 June
Schmidt J (1989) J Chromatogr 485:421–432
Snyder LR, Dolan JW, Lommen DC (1989) J Chromatogr 485:65–89
Haber P, Baczek T, Kaliszan R, Snyder LR, Dolan JW, Wehr CT (2000) J Chromatogr Sci 38:386–392
Jupille TH, Dolan JW, Snyder LR, Molnar I (2002) J Chromatogr A 948:35–41
Araujo P (2000) Trends Anal Chem 19:524–529
Gennaro MC, Marengo E, Gianotti V, Angioi S (2002) J Chromatogr A 945:287–292
Chen J, Glancy K, Chen X, Alasandro M (2001) J Chromatogr A 917:63–73
Medenica M, Jancic B, Ivanovic D, Malenovic A (2004) J Chromatogr A 1031:243–248
Ivanovic D, Medenica M, Jancic B, Malenovic A, Markovic S (2004) Chromatographia 60:S87–S92
Malenovic A, Ivanovic D, Medenica M, Jancic B, Markovic S (2004) J Sep Sci 27(13):1087–1092
Ye C, Liu J, Ren F, Okafo N (2000) J Pharm Biomed Anal 23:581–589
Ficarra R, Ficarra P, Tommasini S, Melardi S, Calabro ML, Furlanetto S, Semreen M (2000) J Pharm Biomed Anal 23:169–174
Ficarra R, Calabro ML, Cutroneo P, Tommasini S, Melardi S, Semreen M, Furlanetto S, Ficarra P, Altavilla G (2002) J Pharm Biomed Anal 29:1097–1103
Vander Heyden Y, Nijhuis A, Smeyers-Verbeke J, Vandeginste BGM, Massart DL (2001) J Pharm Biomed Anal 24:723–753
Hund E, Vander Heyden Y, Haustein M, Massart DL, Smeyers-Verbeke J (2000) J Chromatogr A 874:167–185
Ragonese R, Mulholland M, Kalman J (2000) J Chromatogr A 870:45–51
Yekkala R, Lei H, Hoogmartens J, Adams E (2006) J Pharm Biomed Anal 42:71–80
Guidance for Industry: Q3B impurities in new drug products, US Department of Health and Human Service, Food and Drug Administration, CDER, Rockville, USA, November 1997
Martindale W (1996) Martindale The Extra Pharmacopeia. In: Reynolds JEF (ed). Pharmaceutical Press, London
Mihaljica S, Radulovic D, Trbojevic J (2005) Chromatographia 61:25–29
Alverez-Lueje A, Pujol S, Squella JA, Nunez-Vergara LJ (2003) J Pharm Biomed Anal 31:1–9
Baranda AB, Jimenez RM, Alonso RM (2004) J Chromatogr A 1031:275–280
Fiori J, Gotti R, Bertucci C, Cavrini V (2006) J Pharm Biomed Anal 41:176–181
Jabor VAP, Coelho EB, Ifa DR, Bonato PS, Santos NAG, Lanchote VL (2003) J Chromatogr B 796:429–437
Salem II, Idrees J, Tamimi JIA, Farina P (2004) J Chromatogr B 803:201–207
Jabor VAP, Coelho EB, Lanchote VL (2004) J Chromatogr B 813:343–346
Baranda AB, Etxebarria N, Jiménez RM, Alonso RM (2005) J Chromatogr Sci 43:505–512
Baranda AB, Berasaluce O, Jimenerez RM, Alonso RM (2005) Chromatographia 61:447–453